Richard M Novak1, Rachel L D Hart, Joan S Chmiel, John T Brooks, Kate Buchacz. 1. *Department of Medicine, Division of Infectious Diseases, University of Illinois at Chicago, Chicago, IL; †Cerner Corporation, Vienna, VA; ‡Northwestern University Feinberg School of Medicine, Chicago, IL; and §Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
Abstract
OBJECTIVES: The National HIV/AIDS Strategy emphasizes virologic suppression (VS) to reduce HIV incidence in the United States. We assessed temporal trends of and disparities in time to combination antiretroviral therapy (cART) initiation and HIV VS in a large demographically diverse cohort of HIV-infected patients. DESIGN: We included antiretroviral-naive HIV Outpatient Study participants from 2000 to 2013 enrolled within 6 months of their HIV diagnosis who attended ≥2 HIV care-related visits. METHODS: We evaluated time from HIV diagnosis to first use of cART, time from HIV diagnosis to VS, and time from first use of cART to VS. Kaplan-Meier time-to-event curves and Cox proportional hazards models were used to assess temporal trends and correlates of initiating cART and achieving HIV VS (<500 copies per milliliter). RESULTS: Among 1156 HIV Outpatient Study patients [median age, 37 years; 43.2% non-Hispanic/Latino black (NHB), 14.1% Hispanic/Latino], estimated median times from HIV diagnosis to cART initiation and from HIV diagnosis to VS both shortened by >40% during the 13.5-year study period, reaching, respectively, 2.5 and 5.4 months. In multivariable analyses, NHB patients (as compared with non-Hispanic/Latino white) and those who had injected drugs (as compared with those who did not) initiated cART in a less timely fashion. After adjusting for CD4 cell count and viral load at cART initiation, NHB patients and those aged <30 years (compared with ≥40 years) had lower rates of VS. CONCLUSIONS: Despite improvements in HIV treatment over time, patients who were NHB, younger, or used injection drugs had less favorable outcomes.
OBJECTIVES: The National HIV/AIDS Strategy emphasizes virologic suppression (VS) to reduce HIV incidence in the United States. We assessed temporal trends of and disparities in time to combination antiretroviral therapy (cART) initiation and HIV VS in a large demographically diverse cohort of HIV-infectedpatients. DESIGN: We included antiretroviral-naive HIV Outpatient Study participants from 2000 to 2013 enrolled within 6 months of their HIV diagnosis who attended ≥2 HIV care-related visits. METHODS: We evaluated time from HIV diagnosis to first use of cART, time from HIV diagnosis to VS, and time from first use of cART to VS. Kaplan-Meier time-to-event curves and Cox proportional hazards models were used to assess temporal trends and correlates of initiating cART and achieving HIV VS (<500 copies per milliliter). RESULTS: Among 1156 HIV Outpatient Study patients [median age, 37 years; 43.2% non-Hispanic/Latino black (NHB), 14.1% Hispanic/Latino], estimated median times from HIV diagnosis to cART initiation and from HIV diagnosis to VS both shortened by >40% during the 13.5-year study period, reaching, respectively, 2.5 and 5.4 months. In multivariable analyses, NHB patients (as compared with non-Hispanic/Latino white) and those who had injected drugs (as compared with those who did not) initiated cART in a less timely fashion. After adjusting for CD4 cell count and viral load at cART initiation, NHB patients and those aged <30 years (compared with ≥40 years) had lower rates of VS. CONCLUSIONS: Despite improvements in HIV treatment over time, patients who were NHB, younger, or used injection drugs had less favorable outcomes.
Authors: Linda Beer; Heather Bradley; Christine L Mattson; Christopher H Johnson; Brooke Hoots; Roy L Shouse Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Charles F Haines; John A Fleishman; Baligh R Yehia; Bryan Lau; Stephen A Berry; Allison L Agwu; Richard D Moore; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Jun Li; Elizabeth Humes; Jennifer S Lee; Keri N Althoff; Jonathan A Colasanti; Ronald J Bosch; Michael Horberg; Peter F Rebeiro; Michael J Silverberg; Ank E Nijhawan; Angela Parcesepe; John Gill; Sarita Shah; Heidi Crane; Richard Moore; Raynell Lang; Jennifer Thorne; Timothy Sterling; David B Hanna; Kate Buchacz Journal: Open Forum Infect Dis Date: 2022-07-22 Impact factor: 4.423
Authors: Semiu O Gbadamosi; Mary Jo Trepka; Rahel Dawit; Zoran Bursac; Andrea Raymond; Robert A Ladner; Diana M Sheehan Journal: AIDS Behav Date: 2022-05-10
Authors: Terra V Fatukasi; Stephen R Cole; Richard D Moore; William C Mathews; Jessie K Edwards; Joseph J Eron Journal: PLoS One Date: 2017-07-10 Impact factor: 3.240
Authors: Lauren Lipira; Emily C Williams; David Huh; Christopher G Kemp; Paul E Nevin; Preston Greene; Joseph M Unger; Patrick Heagerty; Audrey L French; Susan E Cohn; Janet M Turan; Michael J Mugavero; Jane M Simoni; Michele P Andrasik; Deepa Rao Journal: AIDS Behav Date: 2019-08
Authors: Kate Buchacz; Carl Armon; Frank J Palella; Richard M Novak; Jack Fuhrer; Ellen Tedaldi; Douglas Ward; Cynthia Mayer; Linda Battalora; Kimberly Carlson; Stacey Purinton; Marcus Durham; Jun Li Journal: Open Forum Infect Dis Date: 2020-04-11 Impact factor: 3.835